Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved ...

Kids and teens can also get migraines, but Black and Hispanic children seen in emergency rooms are more likely to have their ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

美国医药行业类似的商业贿赂行为并不少见。去年，梯瓦向美国司法部支付了4.5亿美元和解费，渤健则是在2022年耗费9亿美元才解决了相关诉讼的麻烦，诺华也曾在2020年支付了6.42亿美元平息指控。

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate ...

Live Updates Deep Dive into ABBV's Earnings Call 11:53 am Looking through AbbVie’s earnings call, these growth prospects stood out: 1. Skyrizi & Rinvoq Set to Dominate Immunology Market 2025 revenue ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include ...

Ubrelvy (ubrogepant) is a prescription drug that treats migraine episodes. This drug can interact with certain other medications and some supplements. For example, Ubrelvy can interact with ...